First single breast cancer study to show significant survival,benefit for women switching from tamoxifen to Arimidex ( Alone or inCombination ARNO 95 Trial...)

First single breast cancer study to show significant survival,benefit for women switching from tamoxifen to Arimidex

Alone or in Combination

ARNO 95 Trial Design

· A prospective, randomised, open-label, parallel group, multi-centre study to assess differences in efficacy and safety between postmenopausal women with hormone receptor–positive breast cancer who switched from tamoxifen (20 or 30mg/d taken for 2 years) to ‘Arimidex’ (1mg/d taken for up to an additional 3 years), and those who continued to receive tamoxifen (20 or 30 mg/d taken for up to an additional 3 years).

AstraZeneca

· AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.

ARIMIDEX is a trademark, the property of the AstraZeneca group of companies.

Therapeutic indications of all AIs:

· Anastrozole (Arimidex), AstraZeneca: Treatment of advanced breast cancer in postmenopausal women. Efficacy has not been demonstrated in oestrogen receptor negative patients unless they had a previous positive clinical response tamoxifen. Adjuvant treatment of postmenopausal women with hormone receptor positive invasive breast cancer. Adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

· Letrozole (Femara), Novartis: Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer. Treatment of early invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy. First line treatment in postmenopausal wom
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report

Post Your Comments:

( Alone or inCombination ARNO 95 Trial...)First single breast cancer study to show significant survival,benefit for women switching from tamoxifen to Arimidex,Health